作者
助理经理
曾任职钢材交易员及广告公司主任，所以特别喜欢研究资源类及消费类股票。欢迎来电赐教或交流心得。
电话:
22776779
电邮:
alexni@phillip.com.hk
UMP HEALTHCARE HOLDINGS LTD. (722)
4659
Commentary:
|
Stock: |
UMP Healthcare Holdings Ltd. |
|
1 Month H/L: |
0.86 – 0.75 |
|
Stock Code: |
772.HK |
|
52 week H/L: |
1.212 – 0.622 |
|
Market Cap.: |
HKD 634.133M |
|
Listing date: |
27/11/2015 |
|
Stock Outstanding: |
792,666,555 shares |
|
Listing price: |
2.06 |
|
P/E (TTM): |
17.467x |
|
Chairman & CEO: |
Dr. Sun Yiu Kwong |
|
Dividend: |
0.038 |
|
Major Shareholdes: |
1. Mr. Sun Yiu Kwong – 35.52% |
|
Dividend Yield: |
4.75% |
|
|
2. Chow Tai Fook (Holding)Ltd – 15.04% |
|
|
|
|
|
3. China Resources Medical Holdings Co. Ltd. - 11.99% |
Established in 1990, UMP health care is a healthcare solution provider operating in Hong Kong as well as Macau and Mainland China. The company's business consist of: 1. Hong Kong & Macau corporate healthcare solutions, 2. Clincal healthcare services, and 3. Mainland China healthcare business.
The company released its interim result on the 24th of February, the table below briefly summarised the company's performance:
|
Business segment |
Business description |
Remarks |
|
Hong Kong & Macau Corporate healthcare solutions |
Tailored healthcare plan to corporate customers, for example, insurance companies, whom their policy holders can use the services. Also, corporations can contract the company to provide healthcare services plan to its employees.
|
Revenue increased by 1.8% from HK$122.3 million for 1HFY2021 to HK$124.5 miilion. Contributions mainly attributed by Medical services, due to number of visits from patients seeking Medical services increased. |
|
Hong Kong & Macau Clinical healthcare services |
To provide service to self-paid patients, areas include: - Medical: general practice services. - Specialist service/consultation: cover 18 different specialities. - Dental: dental care, dental check up. Also provide services such as dental implants. - Auxiliary: Physiotherapy, vision & eye care. - Medical imaging - Laboratory services. |
Revenue of this segment increased by 28.1% from HK$213.1 million for 1HFY2021 to HK$273.0 million for 1HFY2022. The increase mainly due to health check-ups and the medical imaging as well as laborator business.
One point to note that specialist business as well as medical imaging business had been of the main contribution to this line of business, according to the group M&A analysis in 2021 annual report.
|
|
Mainland China healthcare business |
Businesses include: - Healthcare check-up business - Company owned clinic to provide outpatient services |
Revenue of this business line incresed by 29.9% from HK$17.5 million to HK$22.7 million.
* Part of the operation that engaged in corporation healthcare solutions as well as professional training of doctors and nurses in mainland China was disposed last year. |
Source: Company's annual reports and interim reports
The company's revenue had been growing steadily for the past seven years, the drop in year 2020 was attributed to the pandmeic. The growth was subsequently picked in year 2021. The company continued to re-adjust their business strategies through re-organising (Mainland China business) and acquistions (Medical imaging business etc). We expect that the company may continue to expand the medical imaging, laboratary services as well as specialist services since these areas had been one of the main revenue driver for the past few years.
投资涉及风险，有可能损失投资本金。你应该咨询专业人士，就本身的投资经验，财务状况，个人目标及风险取向，以提供投资意见。各类产品的风立，请参阅本公司网页http://www.phillip.com.hk「风险披露声明」。
辉立（或其雇员）可能持有本文所述有关的投资产品。此外，辉立（或任何附属公司）随时可能替向报告内容所述及的公司提供服务，招揽或业务往来。
以上资料为辉立拥有并受版权及知识产法保护。除非事先得到辉立明确书面批准，否则不应复制，散播或发布。
